Nightstar Therapeutics’ (NITE) “Outperform” Rating Reaffirmed at Wedbush
A number of other research firms also recently weighed in on NITE. Chardan Capital assumed coverage on shares of Nightstar Therapeutics in a report on Wednesday, January 3rd. They set a buy rating and a $40.00 price target on the stock. Mizuho assumed coverage on shares of Nightstar Therapeutics in a report on Tuesday, February 27th. They set a buy rating and a $20.00 price target on the stock. Six research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average price target of $28.50.
Nightstar Therapeutics (NASDAQ:NITE) opened at $13.15 on Wednesday. The firm has a market cap of $345.85 and a price-to-earnings ratio of -26.30. Nightstar Therapeutics has a twelve month low of $10.05 and a twelve month high of $24.93.
TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/03/11/nightstar-therapeutics-nite-outperform-rating-reaffirmed-at-wedbush.html.
About Nightstar Therapeutics
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.